Mouse monoclonal IgG3 antibody detecting G(D3) ganglioside: A phase I trial in patients with malignant melanoma Academic Article Article uri icon

Overview

MeSH Major

  • Antigens, Neoplasm
  • Genetic Therapy
  • HLA-A2 Antigen
  • Immunologic Factors
  • Immunotherapy, Active
  • Interleukin-2
  • Melanoma
  • Recombinant Fusion Proteins
  • Tumor Cells, Cultured

abstract

  • R24 is an IgG3 mouse monoclonal antibody that identifies GD3, a prominent ganglioside on the surface of melanoma cells and other cells of neuroectodermal origin. Twelve patients with metastatic melanoma were treated with R24 at three dose levels, 8, 80, or 240 mg/m2, over a period of 2 weeks. Peak antibody levels in the serum were dose related and ranged from less than 0.1 to 62 micrograms/ml. Inflammatory reactions (urticaria, pruritus, erythema, subcutaneous ecchymoses) were observed around tumor sites in patients treated at doses greater than or equal to 80 mg/m2. Tumor biopsies during and after treatment showed lymphocyte and mast cell infiltration, mast cell degranulation, and complement deposition. Side effects were mild and were readily controlled by antihistamines. Major tumor regression has been observed in three patients.

publication date

  • June 13, 1985

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1073/pnas.82.4.1242

PubMed ID

  • 3883355

Additional Document Info

start page

  • 1242

end page

  • 6

volume

  • 82

number

  • 4